Dorsey & Whitney Trust CO LLC Has $941,000 Stock Holdings in Sanofi $SNY

Dorsey & Whitney Trust CO LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 20.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,473 shares of the company’s stock after selling 4,998 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Sanofi were worth $941,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Intrust Bank NA grew its stake in Sanofi by 2.5% during the 2nd quarter. Intrust Bank NA now owns 31,582 shares of the company’s stock valued at $1,526,000 after acquiring an additional 762 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Sanofi by 11.8% during the second quarter. Kingsview Wealth Management LLC now owns 6,638 shares of the company’s stock worth $321,000 after purchasing an additional 702 shares during the period. Avantax Advisory Services Inc. grew its position in Sanofi by 10.9% during the second quarter. Avantax Advisory Services Inc. now owns 58,628 shares of the company’s stock valued at $2,832,000 after purchasing an additional 5,747 shares in the last quarter. ProVise Management Group LLC increased its stake in Sanofi by 3.7% in the 2nd quarter. ProVise Management Group LLC now owns 200,396 shares of the company’s stock valued at $9,681,000 after buying an additional 7,183 shares during the period. Finally, Cetera Investment Advisers lifted its position in Sanofi by 7.5% in the 2nd quarter. Cetera Investment Advisers now owns 242,039 shares of the company’s stock worth $11,693,000 after buying an additional 16,960 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY opened at $50.66 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.94 and a current ratio of 1.06. The company has a market cap of $124.40 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The stock has a 50-day moving average of $49.16 and a 200-day moving average of $49.35. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the company earned $2.25 EPS. The company’s revenue for the quarter was down 7.5% on a year-over-year basis. As a group, equities research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on SNY. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Tuesday, November 11th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Finally, Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.